It is a chemicals private limited company based in Hyderabad, Telangana, India, established in 2003.
2003 | Hyderabad, Telangana, India | ActiveGenomik Design Pharmaceuticals Private Limited, a active private limited company, was established on 07 January 2003 in Hyderabad, Telangana, India. Engaging in chemical products within the manufacturing sector, it holds CIN: U24239TG2003PTC040246. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹1.00 M.
It upholds a compliant status. Its leadership includes Venkata Reddy Massireddigari (Director), Enkemi Reddy Mutyala (Director), Venkata Reddy Boilla (Director). Past directors included Munagala Chandra Shakar Reddy, Krishna Swaroop Reddy Kasi Reddy. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No.177, Ida Mallapur,, Hyderabad, Telangana, 500076.
U24239TG2003PTC040246
040246
07 January 2003
₹1.00 M
₹1.00 M
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Genomik Design Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkata Reddy Massireddigari | Director | 02 Jun 2004 | Current |
| Enkemi Reddy Mutyala | Director | 27 Jun 2011 | Current |
| Venkata Reddy Boilla | Director | 27 Jun 2011 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 24 Dec 2015 | Past |
| Pramod Abcsdd | Director | 01 Mar 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Genomik Design Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2017, Genomik Design Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Genomik Design Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Genomik Design Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genomik Design Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Genomik Design Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Progress on Genomik Design Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was documented.
Progress on Enkemi Reddy Mutyala was appointed as a Director was appointed as a Director on 27 Jun 2011 & has been associated with this company since 14 years 6 months . was documented.
The activity Venkata Reddy Boilla was appointed as a Director was appointed as a Director on 27 Jun 2011 & has been associated with this company since 14 years 6 months . was completed.
Venkata Reddy Massireddigari was appointed as a Director was appointed as a Director on 02 Jun 2004 & has been associated with this company since 21 years 6 months . was recorded as a recent event.
Progress on Genomik Design Pharmaceuticals Private Limited was registered on 07 Jan 2003 with Roc Hyderabad & aged 22 years 11 months as per MCA records. was documented.
The CIN of Genomik Design Pharmaceuticals Private Limited is U24239TG2003PTC040246.
Genomik Design Pharmaceuticals Private Limited is headquartered at Plot No.177, Ida Mallapur,, Hyderabad, Telangana, 500076.
Genomik Design Pharmaceuticals Private Limited was incorporated on 07 January 2003.
The current directors of Genomik Design Pharmaceuticals Private Limited are
The primary industry of Genomik Design Pharmaceuticals Private Limited is Manufacturing.
Genomik Design Pharmaceuticals Private Limited is unlisted.
The authorized capital of Genomik Design Pharmaceuticals Private Limited is ₹1.00 M, and the paid-up capital is ₹1.00 M.
The compliance status of Genomik Design Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX